Panelists Announced for Decision Resources Group One-Day Biologics and Biosimilars Seminar in New York City

Panelists Announced for Decision Resources Group One-Day Biologics and Biosimilars Seminar in New York City

Decision Resources GroupBriana Pontremoli, 781-993-2654orDecision Resources GroupElizabeth Marshall, 781-993-2563

Decision Resources Group is pleased to announce a distinguished lineup of speakers who will be joining its well-regarded Competitive Landscape Seminar Series focusing on Biologics and Biosimilars on October 4, 2012 at Le Parker Meridien New York in New York City. The panel discussion will focus on the future success and challenges facing the biologics and biosimilars market.

Moderated by , Director, Biosimilars & Oncology Products, BioTrends Research Group, panelists include:

Panelists will focus on the keys issues affecting the biologics landscape and the emerging biosimilars sector based on the European experience of biosimilars to date and expectations for the U.S. Topics to be discussed will include the anticipated future trends in the biologics market and the challenges and drivers of biosimilar adoption in the U.S. Panelists will share their thoughts on market access for biosimilars, the role of indication extrapolation and automatic substitution, as well as their perspective on appropriate pricing models for brands and biosimilars as this dynamic market segment continues to evolve.

For more information and to register, please visit:

Media interested in attending the seminar should contact Briana Pontremoli at or 781-993-2654 for additional information.

The Competitive Landscape Seminar Series: Biologics and Biosimilars will be held on October 4, 2012. This high-value, one-day seminar has been developed specifically for biopharmaceutical market research executives as well as biologics and biosimilars product teams. Expert analysts from Decision Resources Group companies—Decision Resources and BioTrends Research Group—will share their latest research findings on key biologics and biosimilars trends.

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at .

Suggested Articles

Loretta Itri, M.D. has been helping Immunomedics out with its troubled antibody-drug conjugate. Now, she’s signing on as its chief medical officer.

Light Chain Bioscience, a unit of Swiss biotech Novimmune, has been handed a nice royalty milestone check from partner Takeda.

The fund received money from Chinese organizations inside and outside the biopharma industry, enabling CICC Capital to ease past its financing goal.